- Home
- PRFX vs XRTX Comparison
PRFX vs XRTX Comparison
Compare PRFX & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRFX
- XRTX
- Stock Information
- Founded
- PRFX 2007
- XRTX 2011
- Country
- PRFX Israel
- XRTX Canada
- Employees
- PRFX N/A
- XRTX N/A
- Industry
- PRFX Biotechnology: Pharmaceutical Preparations
- XRTX Pharmaceuticals and Biotechnology
- Sector
- PRFX Health Care
- XRTX Health Care
- Exchange
- PRFX Nasdaq
- XRTX Nasdaq
- Market Cap
- PRFX 2.9M
- XRTX 3.4M
- IPO Year
- PRFX 2020
- XRTX N/A
- Fundamental
- Price
- PRFX $1.40
- XRTX $0.89
- Analyst Decision
- PRFX Hold
- XRTX
- Analyst Count
- PRFX 1
- XRTX 0
- Target Price
- PRFX N/A
- XRTX N/A
- AVG Volume (30 Days)
- PRFX 326.0K
- XRTX 225.4K
- Earning Date
- PRFX 08-14-2025
- XRTX 08-13-2025
- Dividend Yield
- PRFX N/A
- XRTX N/A
- EPS Growth
- PRFX N/A
- XRTX N/A
- EPS
- PRFX N/A
- XRTX N/A
- Revenue
- PRFX N/A
- XRTX N/A
- Revenue This Year
- PRFX N/A
- XRTX N/A
- Revenue Next Year
- PRFX N/A
- XRTX N/A
- P/E Ratio
- PRFX N/A
- XRTX N/A
- Revenue Growth
- PRFX N/A
- XRTX N/A
- 52 Week Low
- PRFX $1.25
- XRTX $0.80
- 52 Week High
- PRFX $16.63
- XRTX $2.98
- Technical
- Relative Strength Index (RSI)
- PRFX 35.72
- XRTX 50.40
- Support Level
- PRFX $1.25
- XRTX $0.81
- Resistance Level
- PRFX $1.44
- XRTX $0.99
- Average True Range (ATR)
- PRFX 0.10
- XRTX 0.08
- MACD
- PRFX 0.01
- XRTX 0.01
- Stochastic Oscillator
- PRFX 50.00
- XRTX 47.37
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.